Astaxanthin attenuates diabetic cardiomyopathy in rats by downregulation of HMGB1/TLR4/NF-kB signaling pathway

Authors:

Abstract
Background: Cardiomyocyte inflammation, oxidative stress, and myocardial metabolic disruption are among the pathologic abnormalities that can result from diabetic cardiomyopathy (DCM), an independent diabetic cardiac disease. Astaxanthin (ASX) possesses anti-inflammatory and antioxidant properties. Objective: to demonstrate the potential underlying mechanisms and cardioprotective impact of ASX in DCM. Material and methods: Thirty male rats were split into: DCM, DCM+ASX, and control (10/group). Evaluations of the following were conducted: tibial length/LVW, Serum cTnI, LDH, CK-MB, glycosylated Hb A1c, Cholesterol and Triglyceride, HOMA-IR index, and Cardiac MDA, SOD, TNF-α, IL-6, IL-10 and Cardiac gene expression of HMGB1, TLR4, and NF-kB. Additionally, the heart was examined histologically and immunohistochemically. Results: The DCM group's cardiac SOD and cardiac IL-10 were dramatically lower than control, but the measured LVW/tibial length, serum glucose, serum insulin, HOMA-IR index, serum glycosylated Hb A1c, serum cholesterol, serum triglyceride, serum cTnI, serum LDH, serum CK-MB, cardiac MDA, cardiac TNF-α, cardiac IL-6, and cardiac gene expression of HMGB1, TLR4, and NF-kB were all dramatically higher in the DCM than the control. The DCM group's TLR4 and NF-kB cardiac immunoreaction was dramatically lower than the control group's. ASX considerably reduced the alterations brought on by diabetic cardiomyopathy.Conclusion: ASX ameliorated diabetic cardiomyopathy by inhibiting the cardiac HMGB1/TLR4/NF-kB signaling cascade and demonstrating anti-inflammatory, antioxidant, hypoglycemic, and lipid-lowering qualities.